TCZ vs ABA head-to-head in #RA after 1-2 prior b/tsDMARDs: SUNSTAR RCT (n=224) didn't hit its primary endpoint (CDAI change at wk 26, p=0.11). But composite response (treatment persistence + LDA + steroid-sparing) favored TCZ: 50.5% vs 35% (p=0.034). @RheumNow #EULAR2026 OP0205

MTX PO split dose MTX (15mg AM + 10mg PM) vs SC in early seropositive #RA in SCOOT RCT (n=252): SC MTX had better EULAR response at 16 wks (OR 0.55, p=0.049) and ↑ transaminitis with oral split. SC MTX remains the preferred route above 15mg/wk. @RheumNow #EULAR2026 OP0206

RENOIR Ph2b pathogenic T-cell depletion rosnilimab RA -Primary endpoint DAS28-CRP change wk12 -2.06 to -2.12 (all doses) vs -1.69 PBO p<0.01 -ACR20/50/70 + CDAI LDA all improved vs PBO -hsCRP reduction across all dose arms -69% CDAI LDA by wk14 -wk 28 extension shows https://t.co/AMfmSded0D

• https://x.com/AurelieRheumo/status/2062456064033906821/photo/1

A new MoA that does not meet it's primary endpoint in RA SPECIFI-RA Ph2b oral TNFR1 signal inhibitor balinatunfib ACR20 wk12 NOT significantly diff vs PBO ~48.5–61.8% across doses vs 52.3% PBO Secondary BALI 200 mg QD: ACR50: 36.9% vs 18.5% (nominal p=0.0179) Mechanistic https://t.co/hmZ93JisiO

• https://x.com/AurelieRheumo/status/2062454356176171351/photo/1
• https://x.com/AurelieRheumo/status/2062454356176171351/photo/1
• https://x.com/AurelieRheumo/status/2062454356176171351/photo/1

#OP0225 at #EULAR2026: In this nationwide French cohort, patients with IMIDs had nearly 2x risk of HPV-related cancers or severe dysplasia versus matched controls. Risk was particularly increased in SLE, reinforcing the importance of HPV vaccination and screening. @RheumNow

#EULAR2026 OP0228 Is there “something in the air?” Data from US Market Scan: poor quality index was associated with increased risk of #SLE. Although causal inference cannot be deduced, seems an important environmental factor. To check air quality assoc with UV index @RheumNow https://t.co/1FOw7RDA9a

• https://x.com/Yuz6Yusof/status/2062453706897981707/photo/1

#EULAR2026 OP0166 In a phase III RCT in dermatomyositis, brepocitinib, first in class selective SyK-i and JAK1-i showed rapid meaningful improvement in cutaneous DM as early as Week 4 vs PBO. Exciting option and is under FDA Priority Review for approval @RheumNow #EULARBest https://t.co/9b0WurgBkN

• https://x.com/Yuz6Yusof/status/2062469410732790078/photo/1

Which ‘CAR’ to drive in #SLE? Comparison of #CD19 #CAR-T #allogenic vs #Autologous ➡️ comparing #molecular #responses from 2 #lupus studies N=12 Both improved cytokine signatures For #IFN & #neutrophils Results similar not identical ?either #POS0678 #EULAR2026 @RheumNow https://t.co/Lcpv3qJ6tU

• https://x.com/Janetbirdope/status/2062454066387566893/photo/1
• https://x.com/Janetbirdope/status/2062454066387566893/photo/1

Rheumatology Shortage Cliff in Australia & USA Australia is facing a deepening rheumatology manpower crisis with direct parallels to the situation in the United States. The Australian Rheumatology Association's 2025 Workforce Report warns that the nation faces a significant https://t.co/qVziLM25JR

#OP0224 at #EULAR2026: Poor air quality may contribute to lupus risk. In a cohort of 8.3 million people, higher AQI exposure and more unhealthy air quality days were associated with increased incident SLE. Adds to evidence linking environmental exposures & autoimmunity. @RheumNow

JAKi vs TNFi in #RA: Swedish registry (n=21,314) shows JAKi carries ↑ risk of hospitalized infections (IRR 1.23) and ~2x viral infection risk after accounting for treatment discontinuation. Treatment selection matters. @RheumNow #EULAR2026 POS0070

Do we really need yet another JAKi? COURAGE-RA RCT phIII JAK1-selective Zemprocitinib RA bDMARDs IR Primary endpoint ACR20 at wk24 79.1% vs 39.7% PBO (p<0.0001) wk24 ACR50: 55.8% vs 22.0% wk 24 DAS28-CRP ≤3.2: 67.0% vs 23.4% No new safety signal Looks very similar to other https://t.co/b0RMBWl4Xx

• https://x.com/AurelieRheumo/status/2062452234504343915/photo/1
• https://x.com/AurelieRheumo/status/2062452234504343915/photo/1
• https://x.com/AurelieRheumo/status/2062452234504343915/photo/1

Low-dose blinatumomab in multidrug-resistant RA 15 pts 96h cycles CD3×CD19 T-cell engager DAS28-CRP: 4.8 → 2.4 3 mo ACR20 100% ACR50 73% ACR70 53% DAS28 remission 33% But... only transient efficacy with 93% relapse after stopping treatment Authors highlight response to https://t.co/GCS6774tJt

• https://x.com/AurelieRheumo/status/2062449001325023619/photo/1
• https://x.com/AurelieRheumo/status/2062449001325023619/photo/1

#EULAR2026 OP0221 Can we refine response measure in #lupusnephritis RCT? Asia Pacific cohort: construct validity of TRM-SLE definition: 1)RCT entry threshold uPCR >1g/g; 2)clinically meaningful response >50% improvement in UPCR; 3)stricter complete response UPCR<0.2g/g @RheumNow https://t.co/dlErgyFMZP

• https://x.com/Yuz6Yusof/status/2062448542627545582/photo/1

#OP0223 at #EULAR2026: Not every lupus nephritis patient may need upfront triple therapy. Using EULAR 2025 prognostic factors, triple therapy significantly improved complete renal response only in high-risk patients, supporting more precision-based treatment approach. @RheumNow https://t.co/F8Kn23YjNr

• https://x.com/DrMiniDey/status/2062448268018364684/photo/1